Nuclear Probes for Assessing Myocardial Viability in Heart Failure

Heart Failure Clinics

Volumn 2, Issue 2, 2006, Pages 129-143

  Arrighi, James A ^a   Dilsizian, Vasken ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; ACETIC ACID C 11; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; LISINOPRIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PALMITIC ACID C 11; TECHNETIUM 99M; THALLIUM 201;

CELL MEMBRANE; CELL VIABILITY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE METABOLISM; HEART PERFUSION; HEART TRANSPLANTATION; HUMAN; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM;

CELL SURVIVAL; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; PATIENT SELECTION; PEPTIDYL-DIPEPTIDASE A; RADIOPHARMACEUTICALS; TECHNETIUM COMPOUNDS; THALLIUM RADIOISOTOPES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33744908557     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2006.02.002     Document Type: Review

References (87)

1. Heyndrickx G.R., Baig H., Nelkins P., et al. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol 234 (1978) H653-H659
2. Rahimtoola S.H. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 72 Suppl V (1985) V123-V135
3. Braunwald E., and Rutherford J.D. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol 8 (1986) 1467-1470
4. Matsuzaki M., Gallagher K.P., Kemper W.S., et al. Sustained regional dysfunction, produced by prolonged coronary stenosis: gradual recovery after reperfusion. Circulation 68 (1983) 170-182
5. Cleland J.G., Pennell D.J., Ray S.G., et al. Carvedilol hm: myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362 (2003) 14-21
6. Murray C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
7. Taegtmeyer H. Modulation of responses to myocardial ischemia: metabolic features of myocardial stunning, hibernation, and ischemic preconditioning. In: Dilsizian V. (Ed). Myocardial viability: a clinical and scientific treatise (2000), Futura Publishing Company, Inc., Armonk (NY) 25-36
8. Pohost G.M., Zir L.M., Moore R.H., et al. Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201. Circulation 55 (1977) 294-302
9. Leppo J.A., Macneil P.B., Moring A.F., et al. Separate effects of ischemia, hypoxia, and contractility on thallium-201 kinetics in rabbit myocardium. J Nucl Med 27 (1986) 66-74
10. Leppo J.A. Myocardial uptake of thallium and rubidium during alterations in perfusion and oxygenation in isolated rabbit hearts. J Nucl Med 28 (1987) 878-885
11. Dilsizian V., Rocco T.P., Freedman N.M., et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 323 (1990) 141-146
12. 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary artery bypass surgery in patients with severely depressed left ventricular function. Circulation 87 (1993) 1630-1641
13. Dellegrottaglie S., Perrone-Filardi P., Pace L., et al. Prediction of long-term effects of revascularization on regional and global left ventricular function by dobutamine echocardiography and rest Tl-201 imaging alone and in combination in patients with chronic coronary artery disease. J Nucl Cardiol 9 2 (2002) 174-182
14. Bax J.J., Maddahi J., Poldermans D., et al. Sequential (201)Tl imaging and dobutamine echocardiography to enhance accuracy of predicting improved left ventricular ejection fraction after revascularization. J Nucl Med 43 6 (2002) 795-802
15. Tadamura E., Mamede M., Kubo S., et al. The effect of nitroglycerin on myocardial blood flow in various segments characterized by rest-redistribution thallium SPECT. J Nucl Med 44 5 (2003) 745-751
16. Kiat H., Maddahi J., Roy L.T., et al. Comparison of technetium-99m methoxy isobutyl isonitrile and thallium 201 for evaluation of coronary artery disease by planar and tomographic methods. Am Heart J 117 (1989) 1-11
17. Kahn J.K., McGhie I., Akers M.S., et al. Quantitative rotational tomography with T1-201 and Tc-99m 2-methoxy-isobutyl-isonitrile: a direct comparison in normal individuals and patients with coronary artery disease. Circulation 79 (1989) 1282-1293
18. Verani M.S., Jeroudi M.O., Mahmarian J.J., et al. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxybutyl isonitrile. J Am Coll Cardiol 12 (1988) 1573-1581
19. Gibbons R.J., Verani M.S., Behrenbeck T., et al. Feasibility of tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of acute treatment in myocardial infarction. Circulation 80 (1989) 1277-1286
20. Lodge M.A., Braess H., Mahmood F., et al. Developments in nuclear cardiology: transition from single photon emission computed tomography to positron emission tomography-computed tomography. J Invasive Cardiol 17 9 (2005) 491-496
21. 13N-ammonia myocardial blood flow and uptake: relation to functional outcome of asynergic regions after revascularization. J Am Coll Cardiol 33 (1999) 678-686
22. Iida H., Kanno I., Takahashi A., et al. Measurement of absolute myocardial blood flow with O-15 water and dynamic positron emission tomography. Circulation 78 (1988) 104-115
23. Yamamoto Y., de Silva R., Rhodes C.G., et al. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 15O-water and dynamic positron emission tomography. Circulation 86 (1992) 167-178
24. Gould K.L., Yoshida K., Hess M.J., et al. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med 32 (1991) 1-9
25. vom Dahl J., Muzik O., Wolfe E.R., et al. Myocardial rubidium-82 tissue kinetics assessed by dynamic positron emission tomography as a marker of myocardial cell membrane integrity and viability. Circulation 93 (1996) 238-245
26. Gewirtz H., Fischman A.J., Abraham S., et al. Positron emission tomographic measurements of absolute regional myocardial blood flow permits identification of nonviable myocardium in patients with chronic myocardial infarction. J Am Coll Cardiol 23 (1994) 851-859
27. Bennett S.K., Smith M.F., Gottlieb S.S., et al. Effect of metoprolol on absolute myocardial blood flow in patients with heart failure secondary to ischemic or non-ischemic cardiomyopathy. Am J Cardiol 89 (2002) 1431-1434
28. Phelps M.E., Schelbert H.R., and Mazziotta J.C. Positron computer tomography for studies of myocardial and cerebral function. Ann Intern Med 98 (1983) 339-359
29. 123I]-iodophenyl-pentadecanoic acid (BMIPP) identifies ischemic memory following demand ischemia. Circulation 112 14 (2005) 2169-2174
30. Gropler R.J., Geltman E.M., Sampathkumaran K., et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 20 (1992) 569-577
31. Wolpers H.G., Burchert W., van den Hoff J., et al. Assessment of myocardial viability by use of 11C-acetate and positron emission tomography. Threshold criteria of reversible dysfunction. Circulation 95 (1997) 1417-1424
32. 18F]fluorobenzoyllisinopril: a radioligand for angiotensin converting enzyme (ACE) imaging with positron emission tomography. J Labelled Comp Radiopharm 44 (2001) S268-S270
33. 18F] fluorobenzoyl-lisinopril to angiotensin converting enzyme in human heart tissue of ischemic cardiomyopathy. Circulation 104 (2001) II-694
34. Dilsizian V., Loredo M.L., Ferrans V.J., et al. Evidence for increased angiotensin II type I receptor immunoreactivity in peri-infarct myocardium of human explanted hearts. J Am Coll Cardiol 39 (2002) 365A
35. Shirani J., Loredo M.L., Eckelman W.C., et al. Imaging the renin angiotensin aldosterone system in the heart. Curr Heart Fail Rep 2 2 (2005) 78-86
36. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 (2003) 54-59
37. Klocke F.J., Baird M.G., Bateman T.M., et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 108 11 (2003) 1404-1418
38. Kiat H., Berman D.S., Maddahi J., et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 12 (1988) 1456-1463
39. Kayden D.S., Sigal S., Soufer R., et al. Thallium-201 for assessment of myocardial viability: quantitative comparison of 24-hour redistribution imaging with imaging after reinjection at rest. J Am Coll Cardiol 18 (1991) 1480-1486
40. Bonow R.O., Dilsizian V., Cuocolo A., et al. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with F-18 fluorodeoxyglucose. Circulation 83 (1991) 26-37
41. 18F-fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability?. Circulation 97 (1998) 843-850
42. Dilsizian V., Bacharach S.L., Maung K.M., et al. Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: clinical and technological issues. J Nucl Cardiol 8 (2001) 75-88
43. Shirani J., Lee J., Quigg R.J., et al. Relation of thallium uptake to morphologic features of chronic ischemic heart disease: evidence for myocardial remodeling in non-infarct myocardium. J Am Coll Cardiol 38 (2001) 84-90
44. Kitsiou A.N., Srinivasan G., Quyyumi A.A., et al. Stress-induced reversible and mild-to-moderate irreversible thallium defects: are they equally accurate for predicting recovery of regional left ventricular function after revascularization?. Circulation 98 (1998) 501-508
45. 18F-fluorodeoxyglucose. Circulation 89 (1994) 578-587
46. Dilsizian V. Technetium-99m labeled myocardial perfusion tracers: blood flow or viability agents?. In: Dilsizian V. (Ed). Myocardial viability: a clinical and scientific treatise (2000), Futura Publishing Company, Inc., Armonk (NY) 315-348
47. 99mTc-sestamibi. Circulation 89 (1994) 2552-2561
48. Galli M., Marcassa C., Imparato A., et al. Effects of nitroglycerin by technetium-99m sestamibi tomoscintigraphy on resting regional myocardial hypoperfusion in stable patients with healed myocardial infarction. Am J Cardiol 74 (1994) 843-848
49. Bisi G., Sciagra R., Santoro G.M., et al. Sublingual isosorbide dinitrate to improve technetium-99m-teboroxime perfusion defect reversibility. J Nucl Med 35 (1994) 1274-1278
50. Senior R., Kaul S., Raval U., et al. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 9 5 (2002) 454-462
51. Sciagra R., Leoncini M., Marcucci G., et al. Technetium-99m sestamibi imaging to predict left ventricular ejection fraction outcome after revascularisation in patients with chronic coronary artery disease and left ventricular dysfunction: comparison between baseline and nitrate-enhanced imaging. Eur J Nucl Med 28 6 (2001) 680-687
52. Giorgetti A., Marzullo P., Sambuceti G., et al. Baseline/post-nitrate Tc-99m tetrofosmin mismatch for the assessment of myocardial viability in patients with severe left ventricular dysfunction: comparison with baseline Tc-99m tetrofosmin scintigraphy/FDG PET imaging. J Nucl Cardiol 11 2 (2004) 142-151
53. Acampa W., Cuocolo A., Petretta M., et al. Tetrofosmin imaging in the detection of myocardial viability in patients with previous myocardial infarction: comparison with sestamibi and Tl-201 scintigraphy. J Nucl Cardiol 9 1 (2002) 33-40
54. Giorgetti A., Pingitore A., Favilli B., et al. Baseline/postnitrate tetrofosmin SPECT for myocardial viability assessment in patients with postischemic severe left ventricular dysfunction: new evidence from MRI. J Nucl Med 46 8 (2005) 1285-1293
55. Levine M.G., McGill C.C., Ahlberg A.W., et al. Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. Am J Cardiol 83 (1999) 1-5
56. Leoncini M., Sciagra R., Bellandi F., et al. Low-dose dobutamine nitrate-enhanced technetium 99m sestamibi gated SPECT versus low-dose dobutamine echocardiography for detecting reversible dysfunction in ischemic cardiomyopathy. J Nucl Cardiol 9 4 (2002) 402-406
57. Slart R.H., Bax J.J., Sluiter W.J., et al. Added value of attenuation-corrected Tc-99m tetrofosmin SPECT for the detection of myocardial viability: comparison with FDG SPECT. J Nucl Cardiol 11 6 (2004) 689-696
58. DiCarli M.F., Prceevski P., Singh T.P., et al. Myocardial blood flow, function, and metabolism in repetitive stunning. J Nucl Med 41 (2000) 1227-1234
59. Dilsizian V., and Narula J. Nuclear investigation in heart failure and myocardial viability. In: Dilsizian V., and Narula J. (Eds). Atlas of nuclear cardiology. 2nd edition (2006), Current Medicine, Inc., Philadelphia 211-236
60. Tillisch J.H., Brunken R., Marshall R., et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314 (1986) 884-888
61. Tamaki N., Yonekura Y., Yamashita K., et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 64 (1989) 860-865
62. Gerber B.L., Ordoubadi F.F., Wijns W., et al. Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability. Eur Heart J 22 18 (2001) 1691-1701
63. Schwaiger M., Brunken R., Grover-McKay M., et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol 8 (1986) 800-808
64. Kuhl H.P., Beek A.M., van der Weerdt A.P., et al. Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 41 (2003) 1341-1348
65. Knuesel P.R., Nanz D., Wyss C., et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation 108 (2003) 1095-1100
66. DiCarli M.F., Davidson M., Little R., et al. Value of metabolic imaging with positron emission tomography for evaluation prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 73 (1994) 527-533
67. Eitzman D., Al-Aouar Z., Kanter H.L., et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 20 (1992) 559-565
68. Lee K.S., Marwick T.H., Cook S.A., et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: relative efficacy of medical therapy and revascularization. Circulation 90 (1994) 2687-2694
69. Gioia G., Powers J., Heo J., et al. Prognostic value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardiol 75 (1995) 759-762
70. Gioia G., Milan E., Giubbini R., et al. Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction. J Nucl Cardiol 3 2 (1996) 150-156
71. Samady H., Elefteriades J.A., Abbott B.G., et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation 100 12 (1999) 1298-1304
72. Haas F., Augustin N., Holper K., et al. Time course and extent of improvement of dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function after revascularization: correlation with positron emission tomographic findings. J Am Coll Cardiol 36 6 (2000) 1927-1934
73. Santana C.A., Shaw L.J., Garcia E.V., et al. Incremental prognostic value of left ventricular function by myocardial ECG-gated FDG PET imaging in patients with ischemic cardiomyopathy. J Nucl Cardiol 11 5 (2004) 542-550
74. Sawada S., Hamoui O., Barclay J., et al. Usefulness of positron emission tomography in predicting long-term outcome in patients with diabetes mellitus and ischemic left ventricular dysfunction. Am J Cardiol 96 1 (2005) 2-8
75. Beanlands R.S., Ruddy T.D., deKemp R.A., et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 40 10 (2002) 1735-1743
76. Marwick T.H., Nemec J.J., Lafont A., et al. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol 69 9 (1992) 854-859
77. Di Carli M.F., Asgarzadie F., Schelbert H.R., et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 92 12 (1995) 3436-3444
78. Rohatgi R., Epstein S., Henriquez J., et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 87 9 (2001) 1096-1099
79. Di Carli M.F., Maddahi J., Rokhsar S., et al. Long-term survival of patients with chronic coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 116 (1998) 997-1004
80. Desideri A., Cortigiani L., Christen A.I., et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 46 7 (2005) 1264-1269
81. Pagley P.R., Beller G.A., Watson D.D., et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 96 3 (1997) 793-800
82. Siebelink H.M., Blanksma P.K., Crijns H.J., et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 37 1 (2001) 81-88
83. Haas F., Haehnel C.J., Picker W., et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 30 (1997) 1693-1700
84. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 7 (2002) 1151-1158
85. Akinboboye O.O., Idris O., Cannon P.J., et al. Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation. Am J Cardiol 83 (1999) 1271-1274
86. Auerbach M.A., Schoder H., Hoh C., et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 99 (1999) 2921-2926
87. Hunt S.A., Baker D.W., and Chin M.H. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 38 (2001) 2101-2113